// App-Quantinova.ai

3000 : ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.

Researchers

Presenter

  • Timothy Anthony Yap

Principal Investigators

  • Shivaani Kummar

  • Gerald Steven Falchook

  • Russell Kent Pachynski

  • Patricia Lo Russo

  • Scott S. Tykodi

  • Geoffrey Thomas Gibney

  • Justin F. Gainor

  • Osama E. Rahma

  • Tanguy Y. Seiwert

  • Funda Meric-Bernstam

  • Mariela A. Blum Murphy

  • Jennifer Keating Litton

  • Ellen Michelle Diament Hooper

  • Heather Anne Hirsch

  • Christopher Harvey

  • Myles Clancy

  • Ty McClure

  • Margaret K. Callahan

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Sarah Cannon Research Institute, Nashville, TN

  • Division of Cancer Treatment and Diagnosis, Natl Cancer Inst, Bethesda, MD

  • Sarah Cannon Research Institute, Denver, CO

  • Washington University School of Medicine, St. Louis, MO

  • Yale University School of Medicine and Yale Cancer Center, New Haven, CT

  • University of Washington and Fred Hutchinson Cancer Center, Seattle, WA

  • Moffitt Cancer Center, Tampa, FL

  • Massachusetts General Hospital, Boston, MA

  • University of Virgina, Charlottesville, VA

  • Section of Urology, Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, IL

  • Jounce Therapeutics, Cambridge, MA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02904226

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved